Abstract Number: 265 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still’s Disease. Multicenter Study of 75 Patients
Background/Purpose: Interleukin (IL)-1 and IL-6 are pivotal cytokines in the pathogenesis of adult-onset Still’s disease (AOSD). Our aim was to compare the efficacy and safety of…Abstract Number: 266 • 2015 ACR/ARHP Annual Meeting
Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Nonsteroidal anti-inflammatory drugs or corticosteroids are first-line drugs for treating AOSD.…Abstract Number: 267 • 2015 ACR/ARHP Annual Meeting
Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease
Background/Purpose: CXCL10 is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary…Abstract Number: 268 • 2015 ACR/ARHP Annual Meeting
TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations
Background/Purpose: S100A8 and S100A9 are two calcium-binding proteins that belong to the S100 family, and those are expressed by infiltrating monocytes and neutrophils under inflammatory…Abstract Number: 269 • 2015 ACR/ARHP Annual Meeting
Items of Yamaguchi Criteria Might be Associated with Disease Severity and Prognosis in Adult-Onset Still’s Disease
Background/Purpose: Widely accepted outcome measures for disease activity and severity at Adult Onset Still's Disease (AOSD) is not developed until now. Predictive factors for worse…Abstract Number: 270 • 2015 ACR/ARHP Annual Meeting
Biologic Agents in Refractory Adult Still’s Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab
Background/Purpose: There is no randomized controlled trial data to guide us for the management of Adult Still’s Disease (AOSD) patients refractory to conventional treatments. We…Abstract Number: 271 • 2015 ACR/ARHP Annual Meeting
Investigating an Auto-Inflammatory Component of COPD That Contributes to Progressive Decline in Lung Function Despite Smoking Cessation
Background/Purpose: Most Chronic Obstructive Pulmonary Disease (COPD) cases result from amplification of normal inflammatory responses due to noxious stimuli like cigarette smoke. Yet, the mechanism by…Abstract Number: 272 • 2015 ACR/ARHP Annual Meeting
Are the Autoimmune/Inflammatory Syndrome Induced By Adjuvants (ASIA) and the Undifferentiated Connective Tissue Disease (UCTD) Related to Each Other? a Case-Control Study of Environmental Exposures
Background/Purpose: The Autoimmune/Inflammatory Syndrome induced by adjuvants (ASIA) [1] is an entity that includes different autoimmune conditions observed after exposure to an adjuvant. Patients with…Abstract Number: 273 • 2015 ACR/ARHP Annual Meeting
Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study
Background/Purpose: In recent years there has been a growing interest in establishing the concept of Undifferentiated CTD (UCTD) and defining its clinical evolution. Remarkable are…Abstract Number: 274 • 2015 ACR/ARHP Annual Meeting
Shrinking Lung Syndrome in Connective Tissue Disease
Background/Purpose: Shrinking lung syndrome (SLS) is a rare a little known complication associated with systemic lupus erythematosus (SLE) and other connective tissue diseases (CTDs). This…Abstract Number: 275 • 2015 ACR/ARHP Annual Meeting
A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease Vs. Idiopathic Pulmonary Fibrosis
Background/Purpose: We compared clinical features, longitudinal pulmonary physiology, and survival among 3 groups of patients evaluated at our center between February 2008 to August 2014:…Abstract Number: 276 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcome in Mixed Connective Tissue Disease
Background/Purpose: The question of whether mixed connective tissue disease (MCTD) is a distinct entity still remains controversial. For this reason, we have investigated the long-term…Abstract Number: 277 • 2015 ACR/ARHP Annual Meeting
Rituximab in Refractory Mixed Connective Tissue Disease: An Observational Study
Background/Purpose: To investigate the safety and preliminary efficacy of rituximab (RTX) in patients with refractory mixed connective tissue disease (MCTD) Methods: We evaluated 9 patients in…Abstract Number: 278 • 2015 ACR/ARHP Annual Meeting
Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome
Background/Purpose: Joint Hypermobility Syndrome (JHS) may predispose to ligamentous rupture, joint dislocations, fibromyalgia, premature osteoarthritis and non-articular complications include Mitral Valve Prolapse (MVP) (Barron J…Abstract Number: 279 • 2015 ACR/ARHP Annual Meeting
Ehlers-Danlos Syndrome Hypermobility Type (Type III) Is Associated with Rheumatological Conditions
Background/Purpose: Ehlers-Danlos syndrome is a group of inherited conditions caused by genetic mutations in collagen genes, such as COL5A, COL3A, etc, resulting in defects in…
ACR Meeting Abstracts